{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:59:16Z","timestamp":1790636356190,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":155,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Erythropoietin (EPO) is the primary regulator of bone marrow erythropoiesis. Mouse models have provided evidence that EPO also promotes bone remodeling and that EPO-stimulated erythropoiesis is accompanied by bone loss independent of increased red blood cell production. EPO has been used clinically for three decades to treat anemia in end-stage renal disease, and notably, although the incidence of hip fractures decreased in the United States generally after 1990, it rose among hemodialysis patients coincident with the introduction and subsequent dose escalation of EPO treatment. Given this clinical paradox and findings from studies in mice that elevated EPO affects bone health, we examined EPO treatment as a risk factor for fractures in hemodialysis patients. Relationships between EPO treatment and hip fractures were analyzed using United States Renal Data System (USRDS) datasets from 1997 to 2013 and Consolidated Renal Operations in a Web-enabled Network (CROWNWeb) datasets for 2013. Fracture risks for patients treated with &amp;lt;50 units of EPO\/kg\/week were compared to those receiving higher doses by multivariable Cox regression. Hip fracture rates for 747,832 patients in USRDS datasets (1997\u20132013) increased from 12.0 per 1000 patient years in 1997 to 18.9 in 2004, then decreased to 13.1 by 2013. Concomitantly, average EPO doses increased from 11,900\u2009units\/week in 1997 to 18,300 in 2004, then decreased to 8,800 by 2013. During this time, adjusted hazard ratios for hip fractures with EPO doses of 50\u2013149, 150\u2013299, and\u2009\u2265\u2009300\u2009units\/kg\/week compared to &amp;lt;50\u2009units\/kg\/week were 1.08 (95% confidence interval [CI], 1.01\u20131.15), 1.22 (95% CI, 1.14\u20131.31), and 1.41 (95% CI, 1.31\u20131.52), respectively. Multivariable analyses of 128,941 patients in CROWNWeb datasets (2013) replicated these findings. This study implicates EPO treatment as an independent risk factor for hip fractures in hemodialysis patients and supports the conclusion that EPO treatment may have contributed to changing trends in fracture incidence for these patients during recent decades. Published 2021. This article is a U.S. Government work and is in the public domain in the USA. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4297","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T04:42:35Z","timestamp":1620189755000},"page":"1211-1219","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Erythropoietin treatment and the risk of hip fractures in hemodialysis patients"],"prefix":"10.1093","volume":"36","author":[{"given":"Sukanya","family":"Suresh","sequence":"first","affiliation":[{"name":"Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Wright","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Wright","sequence":"additional","affiliation":[{"name":"Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Abbott","sequence":"additional","affiliation":[{"name":"Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7037-2043","authenticated-orcid":false,"given":"Constance T.","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"issue":"3","key":"2024012713472716400_jbmr4297-bib-0001","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011619","article-title":"Erythropoietin","volume":"3","author":"Bunn","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"2024012713472716400_jbmr4297-bib-0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yexcr.2017.03.008","article-title":"New horizons in hypoxia signaling pathways","volume":"356","author":"Pugh","year":"2017","journal-title":"Exp Cell Res"},{"issue":"8","key":"2024012713472716400_jbmr4297-bib-0003","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7150\/ijbs.9518","article-title":"Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system","volume":"10","author":"Wang","year":"2014","journal-title":"Int J Biol Sci"},{"issue":"1534","key":"2024012713472716400_jbmr4297-bib-0004","first-page":"20","article-title":"The many facets of erythropoietin physiologic and metabolic response","volume":"10","author":"Suresh","year":"2020","journal-title":"Front Physiol"},{"key":"2024012713472716400_jbmr4297-bib-0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41413-019-0060-0","article-title":"Erythropoietin modulates bone marrow stromal cell differentiation","volume":"7","author":"Suresh","year":"2019","journal-title":"Bone Res"},{"key":"2024012713472716400_jbmr4297-bib-0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/ncomms1526","article-title":"Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production","volume":"2","author":"Teng","year":"2011","journal-title":"Nat Commun"},{"issue":"2","key":"2024012713472716400_jbmr4297-bib-0007","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1242\/dev.129.2.505","article-title":"Erythropoietin receptor signalling is required for normal brain development","volume":"129","author":"Yu","year":"2002","journal-title":"Development"},{"issue":"11","key":"2024012713472716400_jbmr4297-bib-0008","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/CIRCULATIONAHA.105.583732","article-title":"Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice","volume":"113","author":"Satoh","year":"2006","journal-title":"Circulation"},{"issue":"10","key":"2024012713472716400_jbmr4297-bib-0009","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.lfs.2006.11.023","article-title":"Erythropoietin (EPO): EPO-receptor signaling improves early endochondral ossification and mechanical strength in fracture healing","volume":"80","author":"Holstein","year":"2007","journal-title":"Life Sci"},{"issue":"2","key":"2024012713472716400_jbmr4297-bib-0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jor.21219","article-title":"Low dose erythropoietin stimulates bone healing in mice","volume":"29","author":"Garcia","year":"2011","journal-title":"J Orthop Res"},{"issue":"5","key":"2024012713472716400_jbmr4297-bib-0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010853","article-title":"Erythropoietin couples hematopoiesis with bone formation","volume":"5","author":"Shiozawa","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"2024012713472716400_jbmr4297-bib-0012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0022034514566431","article-title":"Erythropoietin promotes bone formation through EphrinB2\/EphB4 signaling","volume":"94","author":"Li","year":"2015","journal-title":"J Dent Res"},{"issue":"4","key":"2024012713472716400_jbmr4297-bib-0013","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17453674.2016.1198200","article-title":"Increased bone formation in a rabbit long-bone defect model after single local and single systemic application of erythropoietin","volume":"87","author":"Omlor","year":"2016","journal-title":"Acta Orthop"},{"issue":"11","key":"2024012713472716400_jbmr4297-bib-0014","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.joms.2008.06.082","article-title":"Effects of recombinant human erythropoietin on mandibular distraction osteogenesis","volume":"67","author":"Mihmanli","year":"2009","journal-title":"J Oral Maxil Surg"},{"issue":"5","key":"2024012713472716400_jbmr4297-bib-0015","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1096\/fj.14-259085","article-title":"Erythropoietin directly stimulates osteoclast precursors and induces bone loss","volume":"29","author":"Hiram-Bab","year":"2015","journal-title":"FASEB J"},{"issue":"21","key":"2024012713472716400_jbmr4297-bib-0016","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1182\/blood-2010-11-320564","article-title":"Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment","volume":"117","author":"Singbrant","year":"2011","journal-title":"Blood"},{"key":"2024012713472716400_jbmr4297-bib-0017","doi-asserted-by":"crossref","first-page":"11685","DOI":"10.1096\/fj.202000888R","article-title":"Erythropoietin signaling in osteoblasts is required for normal bone formation and for bone loss during erythropoietin-stimulated erythropoiesis","volume":"34","author":"Suresh","year":"2020","journal-title":"FASEB J"},{"issue":"19","key":"2024012713472716400_jbmr4297-bib-0018","doi-asserted-by":"crossref","first-page":"8744","DOI":"10.7150\/thno.45845","article-title":"Erythropoietin receptor in B cells plays a role in bone remodeling in mice","volume":"10","author":"Deshet-Unger","year":"2020","journal-title":"Theranostics"},{"issue":"5","key":"2024012713472716400_jbmr4297-bib-0019","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000356193","article-title":"Physiology and pharmacology of erythropoietin","volume":"40","author":"Jelkmann","year":"2013","journal-title":"Transfus Med Hemother"},{"issue":"8517","key":"2024012713472716400_jbmr4297-bib-0020","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(86)92192-6","article-title":"Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis","volume":"2","author":"Winearls","year":"1986","journal-title":"Lancet"},{"issue":"2","key":"2024012713472716400_jbmr4297-bib-0021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J Med"},{"issue":"4","key":"2024012713472716400_jbmr4297-bib-0022","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1523-1755.2005.00226.x","article-title":"Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program","volume":"67","author":"El-Achkar","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"2024012713472716400_jbmr4297-bib-0023","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.kint.2017.07.021","article-title":"Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation","volume":"92","author":"Pimentel","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"2024012713472716400_jbmr4297-bib-0024","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/jbmr.1684","article-title":"Recent trends in hip fracture rates by race\/ethnicity among older US adults","volume":"27","author":"Wright","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024012713472716400_jbmr4297-bib-0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00198-017-4345-0","article-title":"Hip fracture trends in the United States, 2002 to 2015","volume":"29","author":"Lewiecki","year":"2018","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024012713472716400_jbmr4297-bib-0026","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2215\/CJN.10901012","article-title":"Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States","volume":"8","author":"Nair","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2024012713472716400_jbmr4297-bib-0027","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1053\/j.ajkd.2013.02.368","article-title":"Trends in hip fracture rates in US hemodialysis patients, 1993-2010","volume":"62","author":"Arneson","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2024012713472716400_jbmr4297-bib-0028","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gft352","article-title":"Increased bone fractures among elderly United States hemodialysis patients","volume":"29","author":"Wagner","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2024012713472716400_jbmr4297-bib-0029","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.2215\/CJN.01590215","article-title":"Association of erythropoietin dose and route of administration with clinical outcomes for patients on hemodialysis in the United States","volume":"10","author":"Wright","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024012713472716400_jbmr4297-bib-0030","year":"1994"},{"issue":"3","key":"2024012713472716400_jbmr4297-bib-0031","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1681\/ASN.V103610","article-title":"Hematocrit level and associated mortality in hemodialysis patients","volume":"10","author":"Ma","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2024012713472716400_jbmr4297-bib-0032","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1681\/ASN.V1061309","article-title":"Hematocrit levels and hospitalization risks in hemodialysis patients","volume":"10","author":"Xia","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2024012713472716400_jbmr4297-bib-0033","year":"2007"},{"issue":"20","key":"2024012713472716400_jbmr4297-bib-0034","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"issue":"20","key":"2024012713472716400_jbmr4297-bib-0035","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"2024012713472716400_jbmr4297-bib-0036","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"2024012713472716400_jbmr4297-bib-0037","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.ajkd.2012.04.001","article-title":"The DOPPS practice monitor for US dialysis care: trends through August 2011","volume":"60","author":"Pisoni","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2024012713472716400_jbmr4297-bib-0038","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp068296","article-title":"Medicare and erythropoietin","volume":"356","author":"Steinbrook","year":"2007","journal-title":"N Engl J Med"},{"key":"2024012713472716400_jbmr4297-bib-0039","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12882-015-0059-8","article-title":"Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study","volume":"16","author":"Monda","year":"2015","journal-title":"BMC Nephrol"},{"issue":"2","key":"2024012713472716400_jbmr4297-bib-0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ki.2009.413","article-title":"An improved comorbidity index for outcome analyses among dialysis patients","volume":"77","author":"Liu","year":"2010","journal-title":"Kidney Int"},{"issue":"8","key":"2024012713472716400_jbmr4297-bib-0041","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2215\/CJN.11651115","article-title":"Geovariation in fracture risk among patients receiving hemodialysis","volume":"11","author":"Wetmore","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2024012713472716400_jbmr4297-bib-0042","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2215\/CJN.09280915","article-title":"Bone parameters and risk of hip and femur fractures in patients on hemodialysis","volume":"11","author":"Fishbane","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2024012713472716400_jbmr4297-bib-0043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jbmr.3900","article-title":"High plasma erythropoietin predicts incident fractures in elderly men with normal renal function: the MrOS Sweden cohort","volume":"35","author":"Kristjansdottir","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024012713472716400_jbmr4297-bib-0044","doi-asserted-by":"crossref","first-page":"14989","DOI":"10.1038\/s41598-019-51577-z","article-title":"Elevated FGF23 and disordered renal mineral handling with reduced bone mineralization in chronically erythropoietin over-expressing transgenic mice","volume":"9","author":"Daryadel","year":"2019","journal-title":"Sci Rep"},{"key":"2024012713472716400_jbmr4297-bib-0045","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fphys.2019.00304","article-title":"The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research","volume":"10","author":"van Vuren","year":"2019","journal-title":"Front Physiol"},{"key":"2024012713472716400_jbmr4297-bib-0046","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4614-0887-1_8","article-title":"FGF23 in chronic kidney disease","volume":"728","author":"Wahl","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"2024012713472716400_jbmr4297-bib-0047","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00467-012-2309-3","article-title":"FGF23 production by osteocytes","volume":"28","author":"Bonewald","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2024012713472716400_jbmr4297-bib-0048","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jbmr.4195","article-title":"C-terminal, but not intact, FGF23 and EPO are strongly correlatively elevated in patients with gain-of-function mutations in HIF2A: clinical evidence for EPO regulating FGF23","volume":"36","author":"Roszko","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024012713472716400_jbmr4297-bib-0049","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00424-018-2171-7","article-title":"Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men","volume":"470","author":"Daryadel","year":"2018","journal-title":"Pflugers Arch"},{"issue":"12","key":"2024012713472716400_jbmr4297-bib-0050","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","article-title":"Effects of erythropoietin on fibroblast growth factor 23 in mice and humans","volume":"34","author":"Hanudel","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2024012713472716400_jbmr4297-bib-0051","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.2215\/CJN.02190218","article-title":"Proton pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis","volume":"13","author":"Vangala","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2024012713472716400_jbmr4297-bib-0052","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.ajkd.2019.07.015","article-title":"Selective serotonin reuptake inhibitor use and hip fracture risk among patients on hemodialysis","volume":"75","author":"Vangala","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2024012713472716400_jbmr4297-bib-0053","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE Trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/7\/1211\/55457674\/jbmr4297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/7\/1211\/55457674\/jbmr4297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:07:03Z","timestamp":1710328023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/7\/1211-1219\/7516683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4297","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740063828.793589475","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}